Literature DB >> 629636

Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma.

F Cabanillas, J S Burke, T L Smith, T E Moon, J J Butler, V Rodriguez.   

Abstract

Knowledge of the prognostic factors that characterize a disease can assist in planning and analyzing clinical trials. The present study was conducted to determine the characteristics related to response and survival in patients with stage III and IV non-Hodgkin's lymphoma who were treated with combinations of cyclophosphamide, vincristine sulfate, and prednisone. Considering each characteristic individually and using stepwise regression analysis, tumor bulkiness, prior therapy, sex, and pretreatment lymphocyte count were selected as the four most important prognostic variables. Tumor architecture (diffuse or nodular pattern) and cell type, hemoglobin level, and symptoms although not important in predicting response were found to be important in predicting survival. The hemoglobin level had only marginal importance in predicting response. Factors found not be important were age, stage, symptoms, cell type, nodularity, marrow involvement, prior extensive radiotherapy, and bone involvement. A logistic regression equation has been derived that can be used to predict response rate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 629636

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  8 in total

1.  [Significance of clinical and laboratory chemical parameters for the course and prognosis of non-Hodgkin's lymphomas].

Authors:  B Steinke; J Mau
Journal:  Klin Wochenschr       Date:  1986-05-15

2.  Prognostic significance of biochemical markers in African Burkitt's lymphoma.

Authors:  F K N Arthur; L Owusu; F A Yeboah; T Rettig; A Osei-Akoto
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

3.  Cis-dichlorodiammineplatinum (cis-platinum) and etoposide (VP-16) in malignant lymphoma--an effective salvage regimen.

Authors:  I R Judson; E Wiltshaw
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party.

Authors:  R L Hayward; R C Leonard; R J Prescott
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

Review 5.  Prognostic factors in the non-Hodgkin's lymphomas--a time for consensus?

Authors:  J A Child
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

Review 6.  Smoldering mantle cell lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Krystle Nomie; Jorge Romaguera; Makhdum Ahmed; Michael L Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-12-15

Review 7.  Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.

Authors:  Henrik E Mei; Stefanie Schmidt; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2012-11-08       Impact factor: 5.156

8.  Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification.

Authors:  R C Leonard; J Cuzick; I C MacLennan; R I Vanhegan; P H Mackie; C V McCormick
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.